Stay updated on Ecztra 4: Tralokinumab Drug Interaction Clinical Trial
Sign up to get notified when there's something new on the Ecztra 4: Tralokinumab Drug Interaction Clinical Trial page.

Latest updates to the Ecztra 4: Tralokinumab Drug Interaction Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov page's site revision identifier changed from v3.8.0 to v3.8.1, indicating a platform version update.SummaryDifference0.0%

- Check12 days agoChange DetectedThe record describes a completed Phase 1 trial investigating whether tralokinumab affects the metabolism of five CYP-substrate drugs in adults with moderate-to-severe atopic dermatitis. It includes the study’s eligibility criteria, intervention schedule, locations, and measured outcomes.SummaryDifference61%

- Check19 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedAn NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision number is updated.SummaryDifference1%

- Check47 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check54 days agoChange DetectedRemoved the 403 Forbidden content and the Home link from the study details page, removing the previously displayed error text and a direct Home navigation option.SummaryDifference0.5%

Stay in the know with updates to Ecztra 4: Tralokinumab Drug Interaction Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ecztra 4: Tralokinumab Drug Interaction Clinical Trial page.